Innovative Approaches in Developing Universal Donor Islet Cells for Transplantation

The landscape of diabetes treatment is being reshaped by regenerative medicine, particularly through islet cell transplantation. For patients with type 1 diabetes and some with type 2 diabetes who lose significant beta cell function, transplanting insulin-producing islet cells offers a potential cure. However, a persistent obstacle has been immune-mediated rejection, which typically forces recipients to take lifelong immunosuppressive drugs. These drugs carry serious side effects, including increased infection risk, nephrotoxicity, and malignancy. The quest for universal donor islet cells—cells that can be transplanted into any patient without triggering an immune response—has become a central focus. Recent innovations are bringing this vision closer to clinical reality by combining gene editing, encapsulation, stem cell biology, and immunomodulation. This article explores these cutting-edge strategies and the progress being made toward scalable, safe, and effective universal islet cell therapies.

The Immune Rejection Problem: Why Universal Donors Are Needed

Islet cells from cadaveric donors are the current gold standard for transplantation. Even with close HLA matching between donor and recipient, the host immune system recognizes foreign antigens on the graft cells, leading to rejection. Immunosuppressive drugs can control this process, but they are imperfect and toxic. Moreover, the supply of donor islets is severely limited. According to the JCI Insight, fewer than 1% of eligible patients receive islet transplants due to donor scarcity. Universal donor cells—engineered to evade immune detection—would solve both the supply and rejection problems. They could be manufactured in large quantities from renewable sources and used off-the-shelf for any recipient.

Developing such cells requires a multi-pronged approach. The immune system attacks transplanted cells through both innate and adaptive pathways: T cells recognize foreign HLA molecules, natural killer (NK) cells detect missing self-HLA, and macrophages contribute to inflammation. Any universal cell must simultaneously evade T cell recognition, resist NK cell killing, and avoid triggering innate immune cascades. Researchers are tackling these challenges using the following innovative techniques.

Gene Editing to Remove or Modify Immune Triggers

CRISPR‑Cas9 and other gene-editing platforms have become indispensable tools for creating immune‑invisible cells. The major histocompatibility complex (MHC) class I molecules—called HLA‑A, HLA‑B, and HLA‑C in humans—are the primary targets for T cell recognition. By knocking out the beta‑2‑microglobulin gene (B2M), researchers can disrupt all surface expression of HLA class I. This was demonstrated in early studies with human pluripotent stem cells, where B2M‑null cells were resistant to alloreactive T cells.

However, removing all HLA class I creates a new problem: NK cells attack cells lacking self‑HLA through the “missing‑self” response. To prevent NK cell killing, scientists are introducing molecules that inhibit NK activation. For example, expressing HLA‑E and HLA‑G (non‑classical, non‑polymorphic MHC molecules) or the natural killer cell inhibitory receptor ligands can protect edited cells. A study published in STEM CELLS showed that iPSC‑derived beta cells lacking both B2M and overexpressing HLA‑E resisted both T cell and NK cell attack in vitro and in a humanized mouse model.

Another approach is to engineer cells to express immunomodulatory proteins such as CD47, which delivers a “don’t eat me” signal to macrophages. When combined with HLA modifications, CD47 expression significantly reduces macrophage‑mediated phagocytosis. Multiple groups are now building “stealth” islet cells with genetic cassettes that include B2M knockout, HLA‑E expression, and CD47 expression. These triple‑edited cells have shown remarkable survival in immunocompetent animal models.

Beyond genome editing, epigenetic reprogramming of HLA expression is being explored. Instead of permanently knocking out genes, researchers can use CRISPR‑dCas9 fused with repressor domains to silence HLA expression reversibly. This could provide a safety switch, allowing HLA expression to be restored if needed, for example, to monitor cell health. While still experimental, such approaches offer fine‑tuned control over immune evasion.

Encapsulation: Physical Barriers Against Immunity

Encapsulation technology provides a physical shield around islet cells, allowing nutrients and insulin to pass through while blocking immune cells and large antibodies. This method does not require genetic modification of the cells themselves. Two main types exist: microencapsulation (thin hydrogel coatings around single cells or small clusters) and macroencapsulation (larger devices containing many cells). Each has distinct advantages and challenges.

Microencapsulation Advances

Alginate‑based microcapsules have been the most studied. Recent innovations focus on tuning the capsule’s microstructure to reduce fibrous overgrowth (cell encapsulation‐related fibrosis). A breakthrough came from researchers at the MIT and Harvard who modified alginate with triazole‑thiomorpholine dioxide (TMTD) to minimize foreign body reactions. In primate studies, TMTD‑encapsulated human islets maintained function for over six months without immunosuppression.

Another microencapsulation innovation uses layer‑by‑layer nano‑coatings. By applying alternating layers of oppositely charged polymers, researchers create ultrathin, durable shells (< 100 nm) that protect cells while preserving rapid insulin diffusion. This technique has been shown to reduce complement activation and antibody binding in vitro.

Critically, microencapsulation does not protect against small‑molecule immune signals like cytokines, which can damage encapsulated cells through diffusion. To counter this, researchers are embedding cells with antioxidant enzymes (e.g., catalase, superoxide dismutase) or expressing anti‑apoptotic genes within the cells themselves. Combined strategies that pair microencapsulation with genetic engineering of the cells are now being tested.

Macroencapsulation Devices

Larger devices, such as the Encaptra system (developed by Viacyte, now part of Vertex Pharmaceuticals), house stem cell‑derived pancreatic progenitor cells in a semi‑permeable pouch. These devices allow for retrieval—important for safety—but require a vascularization period before cells can sense glucose. Recent iterations incorporate co‑transplantation with mesenchymal stem cells or pro‑angiogenic factors to accelerate blood supply. In a phase 1 clinical trial (NCT02239354), Encaptra cells survived for up to 24 months and produced detectable levels of human C‑peptide in recipients.

The main drawback of macroencapsulation is the mass transfer limitation: the thicker device wall can delay glucose sensing and insulin secretion. To overcome this, researchers are exploring nanoporous membranes with precisely defined pore sizes (20–30 nm) that exclude immune cells and antibodies but allow rapid diffusion. Materials such as silk fibroin and polyethersulfone are being tested for their biocompatibility and durability.

Stem Cell‑Derived Islet Cells: Unlimited Supply

The successful differentiation of human pluripotent stem cells (hPSCs) into functional, insulin‑secreting beta cells has been a decade‑long endeavor. The protocol, established by Melton’s lab at Harvard (published in 2014 and refined since), mimics embryonic pancreatic development through a series of growth factor and small‑molecule signals. The result is SC‑β cells that respond to glucose in a manner similar to adult beta cells, releasing insulin in pulses.

Recent advances have improved the maturity and function of SC‑β cells. Aggregating differentiated cells into islet‑like clusters and culturing them under flow conditions enhances their functionality. Additionally, co‑differentiation with alpha and delta cells (which produce glucagon and somatostatin) creates a more physiologically relevant “organoid” that better regulates insulin release.

The challenge remains: even if SC‑β cells are functionally perfect, they still express the donor’s HLA (from the original stem cell line). Therefore, combining stem cell technology with gene editing to create an immune‑evasive universal line is the logical next step. Several companies and academic groups are now developing “hypoimmunogenic” hPSC lines that can be scaled and banked for off‑the‑shelf use. For example, CRISPR Therapeutics (in collaboration with ViaCyte/Vertex) has created VCTX‑210, a gene‑edited stem cell‑derived islet cell product currently in clinical trials.

Scalability and Manufacturing

One major barrier is the cost and complexity of manufacturing universal donor islet cells. Current differentiation protocols take 3–4 weeks and produce a mixture of cell types. Purifying the final product to remove any undifferentiated cells (which could form teratomas) is critical. Fluorescence‑activated cell sorting (FACS) using specific surface markers (e.g., Ncam1, Pdx1) can achieve >99% purity, but it adds expense. Researchers are developing antibiotic‑free selection systems and suicide genes (e.g., inducible caspase‑9) as safety switches to eliminate any rogue cells post‑transplantation.

Large‑scale production also requires bioreactor technology. Stirred‑tank bioreactors capable of producing billions of cells per batch are being optimized for SC‑β cell differentiation. Companies like Vertex have invested heavily in closed‑system bioreactors that meet GMP (Good Manufacturing Practice) standards. With these systems, a single manufacturing run could yield enough universal islet cells to treat dozens of patients.

Immunomodulatory Strategies Beyond the Cell Itself

Even the most stealthy universal donor cells can still be subject to local inflammation and sensitization over time. To address this, researchers are developing methods to actively regulate the recipient’s immune response at the transplant site.

Local Immunosuppression via Encapsulated Drugs

Rather than systemic immunosuppression, which affects the entire body, scientists are incorporating slow‑release drugs into the encapsulation matrix. For instance, alginate microcapsules can hold a reservoir of tacrolimus or rapamycin that leaches out locally. A 2022 study in Science Translational Medicine demonstrated that islet‐tacrolimus microcapsules significantly prolonged graft survival in nonhuman primates without raising systemic drug levels.

Co‑Delivery of Regulatory Cells

Another emerging approach is to co‑transplant regulatory T cells (Tregs) along with the islet cells. Tregs suppress effector T cell responses and promote tolerance. By engineering the donor islet cells to secrete the Treg‑chemoattractant CCL22, researchers can recruit host Tregs to the graft site. This “tropism” strategy was shown to induce long‑term acceptance of allogeneic islets in mice.

Similarly, mesenchymal stem cells (MSCs) have powerful immunomodulatory properties. When co‑encapsulated with islet cells, MSCs reduce inflammation and enhance islet function. A clinical trial (NCT03959033) is exploring the safety of co‑transplanting islets and MSCs via a macroencapsulation device.

Biomaterial‑Based Immune Modulation

New biomaterials can be designed to present tolerogenic signals to the immune system. For example, coatings with Fas ligand (FasL) induce apoptosis of infiltrating effector T cells. This concept has been tested in islet transplantation with encouraging results: FasL‑coated microcapsules prevented rejection in mice even without gene editing. Another approach uses hydrogels loaded with TGF‑β or IL‑10 to create a local immunoregulatory microenvironment. These “immunoisolation” biomaterials are still preclinical but offer a complementary strategy to cell‑autonomous immune evasion.

Clinical Trials and Ongoing Challenges

Several clinical trials are evaluating universal donor islet cells or closely related approaches. As of 2025, Vertex’s VX‑880 (allogeneic SC‑β cells) is in Phase 1/2 for type 1 diabetes, but recipients still receive immunosuppression. The company’s next‑generation product, VCTX‑210, incorporates gene edits to reduce immunogenicity and is in early clinical testing. Similarly, CRISPR Therapeutics and ViaCyte have a product using gene‑edited stem cells encapsulated in a device, currently in Phase 2 (NCT05210530).

Preliminary results from these trials have been promising: patients show reduced insulin dependence and improved glycemic control. However, challenges remain:

  • Durability: Encapsulated cells often lose function over months due to fibrosis. Better anti‑fibrotic strategies are needed.
  • Safety: Gene‑edited cells carry risk of off‑target mutations; long‑term monitoring is essential.
  • Immune Escape Variants: The immune system may evolve to recognize non‑HLA antigens or small peptides from the edited donor cells. Constant vigilance through periodic surveillance may be required.
  • Cost: A single dose of universal islet cells could cost $100,000–300,000, though prices may decrease with scale.

Ethical and Regulatory Considerations

The development of universal donor islet cells raises important ethical questions. Informed consent from donors of the original stem cell lines must be properly addressed, with transparency about commercial use. For patient recipients, there must be clear discussion about the experimental nature of these products and the unknown long‑term risks, including potential tumorigenicity and germline transmission of edits (though only somatic cells are used).

Regulatory bodies, such as the FDA, have issued draft guidance on gene‑edited cell products, emphasizing the need for comprehensive testing of off‑target effects and immune evasion durability. The International Society for Stem Cell Research (ISSCR) updated its guidelines in 2023 to address the unique challenges of hypoimmunogenic cell therapies, including the requirement for long‑term follow‑up registries.

Another ethical dimension is equity of access. Universal donor islet cells could potentially cure diabetes, but if only wealthy patients can afford them, it will exacerbate health disparities. Governments and insurers will need to consider coverage models. The American Diabetes Association has initiated cost‑effectiveness modeling to project the societal impact of these therapies.

Future Perspectives

The convergence of gene editing, stem cell biology, encapsulation, and immunology is accelerating the path to a viable universal donor islet product. In the next five to ten years, we can expect to see more clinical trials combining multiple immune‑evasion strategies. For example, a product that pairs B2M‑/HLA‑E+ stem cell‑derived beta cells with tolerogenic hydrogel microcapsules and a Treg‑recruiting chemokine could achieve long‑term engraftment without systemic immunosuppression.

Beyond diabetes, the principles of universal donor cells could be applied to other cell replacement therapies, such as dopamine neurons for Parkinson’s disease or cardiomyocytes for heart failure. The islet field is a trailblazer for the entire regenerative medicine industry.

Ultimately, the goal is to create a treatment that is safe, scalable, and affordable. If the technical hurdles can be overcome—particularly fibrosis and long‑term immune evasion—universal donor islet cells could transform the lives of millions of people with insulin‑dependent diabetes, offering a functional cure that eliminates the burden of daily injections and glucose monitoring.

With continued investment and interdisciplinary collaboration, the vision of a worldwide “islet bank” of universal donor cells may become a routine reality within this decade.